報價延遲最少15分鐘:2026/11/04 14:31 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.82 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.32/-4.23
|
|
企業價值
62.73M
|
| 資產負債 |
|
每股賬面淨值
10.98
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
43.77M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Itsintegrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases. |
